Avalo Debt Ratio from 2010 to 2025

AVTX Stock

USD 7.59 0.07 0.91%

Avalo Therapeutics Debt Ratio yearly trend continues to be fairly stable with very little volatility. Debt Ratio will likely drop to 0 in 2025. During the period from 2010 to 2025, Avalo Therapeutics Debt Ratio regression line of annual values had r-squared of 0.54 and arithmetic mean of 0.32. View All Fundamentals

Debt Ratio

First Reported

2010-12-31

Previous Quarter

0.00376828

Current Value

0.00358

Quarterly Volatility

0.24845511

Credit Downgrade

Yuan Drop

Covid

Check Avalo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avalo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 172.6 K, Interest Expense of 5.4 M or Selling General Administrative of 12.5 M, as well as many indicators such as Price To Sales Ratio of 130, Dividend Yield of 0.0 or PTB Ratio of 0.43. Avalo financial statements analysis is a perfect complement when working with Avalo Therapeutics Valuation or Volatility modules.

Check out the analysis of Avalo Therapeutics Correlation against competitors.

For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide.

Latest Avalo Therapeutics' Debt Ratio Growth Pattern

Below is the plot of the Debt Ratio of Avalo Therapeutics over the last few years. It is Avalo Therapeutics' Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avalo Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Debt Ratio

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Debt Ratio

Timeline

Avalo Debt Ratio Regression Statistics

	Arithmetic Mean	0.32
	Geometric Mean	0.13
	Coefficient Of Variation	77.95
	Mean Deviation	0.22
	Median	0.41
	Standard Deviation	0.25
	Sample Variance	0.06
	Range	0.5821
	R-Value	(0.73)
	Mean Square Error	0.03
	R-Squared	0.54
	Significance	0
	Slope	(0.04)
	Total Sum of Squares	0.93

Avalo Debt Ratio History

	2025	0.00358
	2024	0.003768
	2023	0.0256
	2022	0.58
	2020	0.009744
	2019	0.0351

Other Fundumenentals of Avalo Therapeutics

Cash Flow To Debt Ratio

Avalo Therapeutics Debt Ratio component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Short Term Debt	Net Receivables	Net Tangible Assets	Good Will	Net Invested Capital	Net Working Capital	Intangible Assets	Property Plant Equipment	Long Term Debt	Short Long Term Debt	Capital Stock	Capital Surpluse	Deferred Long Term Liab
Total Assets		0.95	-0.89	-0.74	-0.25	0.23	0.96	0.01	0.12	-0.39	0.24	-0.33	-0.58	0.91	0.92	-0.47	0.61	0.1	0.5	-0.18	-0.84	-0.84
Total Stockholder Equity	0.95		-0.94	-0.69	-0.42	-0.06	0.95	0.05	-0.01	-0.43	0.08	-0.39	-0.69	0.92	0.94	-0.48	0.52	0.04	0.46	-0.3	-0.88	-0.88
Net Debt	-0.89	-0.94		0.65	0.48	0.07	-0.97	0.12	0.07	0.36	0.2	0.47	0.78	-0.97	-0.99	0.48	-0.46	0.08	-0.4	0.34	0.92	0.92
Retained Earnings	-0.74	-0.69	0.65		0.08	-0.21	-0.72	0.17	-0.13	0.11	-0.04	0.62	0.72	-0.55	-0.69	0.82	-0.93	-0.11	-0.84	0.36	0.59	0.59
Accounts Payable	-0.25	-0.42	0.48	0.08		0.53	-0.33	-0.02	0.65	0.23	0.42	0.51	0.59	-0.42	-0.39	-0.17	0.21	0.64	0.26	0.66	0.49	0.49
Total Liab	0.23	-0.06	0.07	-0.21	0.53		0.13	-0.16	0.43	0.14	0.51	0.14	0.32	0.07	0.04	-0.01	0.31	0.18	0.14	0.33	0.01	0.01
Total Current Assets	0.96	0.95	-0.97	-0.72	-0.33	0.13		-0.11	0.07	-0.34	-0.01	-0.4	-0.68	0.97	0.99	-0.52	0.57	0.04	0.48	-0.22	-0.9	-0.9
Common Stock	0.01	0.05	0.12	0.17	-0.02	-0.16	-0.11		0.02	-0.12	0.23	0.09	0.1	-0.09	-0.11	0.16	-0.21	-0.08	-0.2	0.06	0.1	0.1
Current Deferred Revenue	0.12	-0.01	0.07	-0.13	0.65	0.43	0.07	0.02		-0.28	0.33	0.58	0.24	-0.02	0.01	-0.26	0.33	0.72	0.31	0.85	0.19	0.19
Short Term Debt	-0.39	-0.43	0.36	0.11	0.23	0.14	-0.34	-0.12	-0.28		-0.25	-0.32	0.3	-0.38	-0.38	0.13	-0.14	-0.42	-0.18	-0.26	0.28	0.28
Net Receivables	0.24	0.08	0.2	-0.04	0.42	0.51	-0.01	0.23	0.33	-0.25		0.45	0.46	-0.08	-0.12	0.13	0.2	0.45	0.17	0.37	0.17	0.17
Net Tangible Assets	-0.33	-0.39	0.47	0.62	0.51	0.14	-0.4	0.09	0.58	-0.32	0.45		0.74	-0.35	-0.44	0.39	-0.39	0.62	-0.29	0.89	0.51	0.51
Good Will	-0.58	-0.69	0.78	0.72	0.59	0.32	-0.68	0.1	0.24	0.3	0.46	0.74		-0.64	-0.75	0.63	-0.55	0.22	-0.51	0.58	0.67	0.67
Net Invested Capital	0.91	0.92	-0.97	-0.55	-0.42	0.07	0.97	-0.09	-0.02	-0.38	-0.08	-0.35	-0.64		0.98	-0.34	0.37	-0.08	0.27	-0.22	-0.92	-0.92
Net Working Capital	0.92	0.94	-0.99	-0.69	-0.39	0.04	0.99	-0.11	0.01	-0.38	-0.12	-0.44	-0.75	0.98		-0.52	0.52	0.0	0.44	-0.27	-0.92	-0.92
Intangible Assets	-0.47	-0.48	0.48	0.82	-0.17	-0.01	-0.52	0.16	-0.26	0.13	0.13	0.39	0.63	-0.34	-0.52		-0.86	-0.45	-0.92	0.12	0.4	0.4
Property Plant Equipment	0.61	0.52	-0.46	-0.93	0.21	0.31	0.57	-0.21	0.33	-0.14	0.2	-0.39	-0.55	0.37	0.52	-0.86		0.37	0.95	-0.11	-0.33	-0.33
Long Term Debt	0.1	0.04	0.08	-0.11	0.64	0.18	0.04	-0.08	0.72	-0.42	0.45	0.62	0.22	-0.08	0.0	-0.45	0.37		0.52	0.7	0.14	0.14
Short Long Term Debt	0.5	0.46	-0.4	-0.84	0.26	0.14	0.48	-0.2	0.31	-0.18	0.17	-0.29	-0.51	0.27	0.44	-0.92	0.95	0.52		-0.07	-0.26	-0.26
Capital Stock	-0.18	-0.3	0.34	0.36	0.66	0.33	-0.22	0.06	0.85	-0.26	0.37	0.89	0.58	-0.22	-0.27	0.12	-0.11	0.7	-0.07		0.43	0.43
Capital Surpluse	-0.84	-0.88	0.92	0.59	0.49	0.01	-0.9	0.1	0.19	0.28	0.17	0.51	0.67	-0.92	-0.92	0.4	-0.33	0.14	-0.26	0.43		1.0
Deferred Long Term Liab	-0.84	-0.88	0.92	0.59	0.49	0.01	-0.9	0.1	0.19	0.28	0.17	0.51	0.67	-0.92	-0.92	0.4	-0.33	0.14	-0.26	0.43	1.0

Click cells to compare fundamentals

About Avalo Therapeutics Financial Statements

Avalo Therapeutics investors use historical fundamental indicators, such as Avalo Therapeutics' Debt Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Avalo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Cash Flow To Debt Ratio	(86.37)	(82.05)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Avalo Stock Analysis

When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Avalo Debt Ratio from 2010 to 2025

Latest Avalo Therapeutics' Debt Ratio Growth Pattern

Avalo Debt Ratio Regression Statistics

Avalo Debt Ratio History

Other Fundumenentals of Avalo Therapeutics

Avalo Therapeutics Debt Ratio component correlations

About Avalo Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Avalo Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY